EXABLATE
Insightec · Decision date Jul 11, 2016
What did the FDA approve?
FDA records P150038 as an original PMA application. The recorded decision is approval, dated Jul 11, 2016.
FDA approval order statement
Approval for the ExAblate Model 4000 Type 1.0 System (ExAblate Neuro). This device is indicated for use in the unilateral Thalamotomy treatment of idiopathic Essential Tremor patients with medication-refractory tremor. Patients must be at least age 22. The designated area in the brain responsible for the movement disorder symptoms (ventralis intermedius) must be identified and accessible for targeted thermal ablation by the ExAblate device.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Jul 11, 2016
Regulatory record facts
- Identifier
- P150038
- Regulatory pathway
- Premarket approval application
- Applicant
- Insightec
- Product code
- POH
- Decision code
- APPR
- Decision date
- Jul 11, 2016
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: MR-guided focused ultrasound system.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150038 received
Application receipt date recorded by FDA.
P150038 · FDA decision
APPR
P150038/S043 · Related supplement
Exablate Model 4000 System
P150038/S042 · Related supplement
Exablate Model 4000 Type 1.0 and 1.1 (Exablate Neuro; Exablate Prime)
P150038/S044 · Related supplement
Exablate Model 4000 System
Timeline entries are records held by MedtechLedger for P150038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150038
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Exablate Model 4000 SystemP150038/S043 | Insightec | PMA supplement | Jan 28, 2026 | FDA |
| Insightec | PMA supplement | Mar 5, 2026 | FDA | |
EXABLATEP150038/S041 | Insightec | PMA supplement | Mar 23, 2026 | FDA |
Exablate Model 4000 SystemP150038/S044 | Insightec | PMA supplement | Sep 16, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Insightec
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5 Nahum Heth St., Tirat Carmel, 39120
Sources and methodology
- Original FDA record: P150038
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


